A new international collaboration backed by a pan-European EUREKA grant aims to develop targeted small-molecule therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene (Nasdaq: EVGN), Systasy Bioscience, and LMU University Hospital Munich announced the partnership on Feb. 11, with additional participation from the Weizmann Institute of Science. The…
